Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (original) (raw)

• Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
• Mehra, K. et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front. Biosci. (Elite Ed) 3, 625–634 (2011).
  Google Scholar
• Lee, Y. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 211, 26–35 (2007).
  Article CAS PubMed Google Scholar
• Piek, J. M. et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195, 451–456 (2001).
  Article CAS PubMed Google Scholar
• Falconer, H., Yin, L., Gronberg, H. & Altman, D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J. Natl. Cancer Inst. 107 (2015).
• Kuhn, E. et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions. J. Pathol. 226, 421–426 (2012).
  Article CAS PubMed Google Scholar
• Kindelberger, D. W. et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161–169 (2007).
  Article PubMed Google Scholar
• Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, J., Coffey, D. M., Ma, L. & Matzuk, M. M. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology 156, 1975–1981 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Howitt, B. E. et al. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am. J. Surg. Pathol. 39, 287–293 (2015).
  Article PubMed Google Scholar
• Yemelyanova, A. et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 24, 1248–1253 (2011).
  Article CAS PubMed Google Scholar
• Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian cancer. Nature 474, 609–615 (2011).
• Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127–1133 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Martins, F. C. et al. Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 15, 526 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).
  Article CAS PubMed Google Scholar
• Mukhopadhyay, A. et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 16, 2344–2351 (2010).
  Article CAS PubMed Google Scholar
• Mukhopadhyay, A. et al. Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival. Cancer Res. 72, 5675–5682 (2012).
  Article CAS PubMed Google Scholar
• Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30, 2654–2663 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Walsh, T. et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc. Natl Acad. Sci. USA 107, 12629–12633 (2010).
  Article PubMed PubMed Central Google Scholar
• Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
  Article CAS PubMed Google Scholar
• Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
  Article CAS PubMed Google Scholar
• Scott, C. L., Swisher, E. M. & Kaufmann, S. H. Poly (adp-ribose) polymerase inhibitors: recent advances and future development. J. Clin. Oncol. 33, 1397–1406 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141–1152 (2014).
  Article CAS PubMed Google Scholar
• Etemadmoghadam, D. et al. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 5, e15498 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008).
  Article CAS PubMed Google Scholar
• Konecny, G. E. et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst. 106, dju249 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pradeep, S. et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 26, 77–91 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, D. et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23, 186–199 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Vecchione, A. et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl Acad. Sci. USA 110, 9845–9850 (2013).
  Article PubMed PubMed Central Google Scholar
• Parikh, A. et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun. 5, 2977 (2014).
  Article CAS PubMed Google Scholar
• Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
  Article CAS PubMed Google Scholar
• Anglesio, M. S. et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE 8, e72162 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013).
  Article CAS PubMed Google Scholar
• Beaufort, C. M. et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS ONE 9, e103988 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• O'Donnell, R. et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 9, e90604 (2014).
  Article PubMed Central Google Scholar
• Ince, T. A. et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun. 6, 7419 (2015).
  Article CAS PubMed Google Scholar
• Kenny, H. A. et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat. Commun. 6, 6220 (2015).
  Article CAS PubMed Google Scholar
• Kenny, H. A. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614–4628 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Karst, A. M. & Drapkin, R. Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat. Protoc. 7, 1755–1764 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Karst, A. M., Levanon, K. & Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl Acad. Sci. USA 108, 7547–7552 (2011).
  Article PubMed PubMed Central Google Scholar
• Jazaeri, A. A. et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13, 899–911 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sherman-Baust, C. A. et al. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J. Pathol. 233, 228–237 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Platt, R. J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Topp, M. D. et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol. Oncol. 8, 656–668 (2014).
  Article PubMed PubMed Central Google Scholar
• Weroha, S. J. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288–1297 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Dobbin, Z. C. et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5, 8750–8764 (2014).
  Article PubMed PubMed Central Google Scholar
• Ricci, F. et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 74, 6980–6990 (2014).
  Article CAS PubMed Google Scholar
• Malaney, P., Nicosia, S. V. & Dave, V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 344, 1–12 (2014).
  Article CAS PubMed Google Scholar
• Cai, S. et al. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin. Cancer Res. 17, 2195–2206 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21–34 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cowin, P. A. et al. LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res. 72, 4060–4073 (2012).
  Article CAS PubMed Google Scholar
• Cooke, S. L. et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 29, 4905–4913 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Schwarz, R. F. et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 12, e1001789 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Stronach, E. A. et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13, 1069–1080 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008–3015 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in _BRCA2_-mutated cancers. Nature 451, 1116–1120 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Blagden, S. et al. Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer. Eur. J. Cancer 50, 7 (2014).
  Article Google Scholar
• Lu, Z. et al. DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10, 1071–1092 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
  Article CAS PubMed Google Scholar
• Marx, V. Cancer: A most exceptional response. Nature 520, 389–393 (2015).
  Article CAS PubMed Google Scholar
• Ye, Q. et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin. Cancer Res. 20, 44–55 (2014).
  Article CAS PubMed Google Scholar
• Kandalaft, L. E., Powell, D. J. Jr, Singh, N. & Coukos, G. Immunotherapy for ovarian cancer: what's next? J. Clin. Oncol. 29, 925–933 (2011).
  Article CAS PubMed Google Scholar
• Wick, D. A. et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 20, 1125–1134 (2014).
  Article CAS PubMed Google Scholar
• Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol. 24, 225–232 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Inaba, T. et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol. Oncol. 115, 185–192 (2009).
  Article CAS PubMed Google Scholar
• Duraiswamy, J., Freeman, G. J. & Coukos, G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900–6912 (2013).
  Article CAS PubMed Google Scholar
• Motz, G. T. & Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 39, 61–73 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kryczek, I. et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900–8905 (2007).
  Article CAS PubMed Google Scholar
• Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
  Article CAS PubMed Google Scholar
• Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• George, J. et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin. Cancer Res. 19, 3474–3484 (2013).
  Article CAS PubMed Google Scholar
• Soslow, R. A. et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod. Pathol. 25, 625–636 (2012).
  Article CAS PubMed Google Scholar
• Fujiwara, M. et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am. J. Surg. Pathol. 36, 1170–1177 (2012).
  Article PubMed PubMed Central Google Scholar
• Clarke, B. et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 22, 393–402 (2009).
  Article CAS PubMed Google Scholar
• Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557–1565 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bjorkman, A. et al. Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells. Proc. Natl Acad. Sci. USA 112, 2157–2162 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Galon, J. et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 232, 199–209 (2014).
  Article CAS PubMed Google Scholar
• Galon, J., Angell, H. K., Bedognetti, D. & Marincola, F. M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013).
  Article CAS PubMed Google Scholar
• Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067–2079 (2013).
  Article PubMed PubMed Central Google Scholar
• Li, H. et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 5, 587–598 (2014).
  PubMed PubMed Central Google Scholar
• Fang, F. et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res. 20, 6504–6516 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Fang, F. et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 5, 3579–3589 (2014).
  PubMed PubMed Central Google Scholar
• Matei, D. et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197–2205 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Nielsen, J. S. et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281–3292 (2012).
  Article CAS PubMed Google Scholar
• Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083–6096 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
  Article CAS PubMed Google Scholar
• Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
  Article CAS PubMed Google Scholar
• Davidowitz, R. A. et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J. Clin. Invest. 124, 2611–2625 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Iwanicki, M. P. et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1, 144–157 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Yeung, T. L. et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73, 5016–5028 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cheon, D. J. et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin. Cancer Res. 20, 711–723 (2014).
  Article CAS PubMed Google Scholar
• Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ahmed, A. A. et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 12, 514–527 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735–747 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article CAS PubMed Google Scholar
• Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
  Article CAS PubMed Google Scholar
• Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107, 1776–1782 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• McNeish, I. A. et al. Results of ARIEL2: A phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. J. Clin. Oncol. 33, 5508 (2015).
  Article Google Scholar
• Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).
  Article CAS PubMed Google Scholar
• Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).
  Article CAS PubMed Google Scholar
• Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).
  Article CAS PubMed Google Scholar
• Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).
  Article CAS PubMed Google Scholar
• Oliver, K. E. & McGuire, W. P. Ovarian cancer and antiangiogenic therapy: caveat emptor. J. Clin. Oncol. 32, 3353–3356 (2014).
  Article CAS PubMed Google Scholar
• Hall, M. et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br. J. Cancer 108, 250–258 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Gourley, G. et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J. Clin. Oncol. 32, 5502 (2014).
  Article Google Scholar
• Choi, H. J. et al. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 34, 19–40 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Zaid, T. M. et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin. Cancer Res. 19, 809–820 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, J. F. et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 15, 1207–1214 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Rubin, E. H., Anderson, K. M. & Gause, C. K. The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development. Cancer Discov. 1, 17–20 (2011).
  Article CAS PubMed Google Scholar
• Cheung, H. W. et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl Acad. Sci. USA 108, 12372–12377 (2011).
  Article PubMed PubMed Central Google Scholar
• Baratta, M. G. et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc. Natl Acad. Sci. USA 112, 232–237 (2015).
  Article CAS PubMed Google Scholar
• Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436–442 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A. & Horowitz, I. R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21, 283–290 (2003).
  Article CAS PubMed Google Scholar
• McKie, A. B. et al. The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov. 2, 156–171 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
  Article PubMed Google Scholar
• Ramos, P. et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat. Genet. 46, 427–429 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Silva, I. A. et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991–4001 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Condello, S. et al. β-catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene 34, 2297–2308 (2015).
  Article CAS PubMed Google Scholar
• Wang, Y. et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74, 4922–4936 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, S. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc. Natl Acad. Sci. USA 111, 17266–17271 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kalinsky, K. & Hershman, D. L. Cracking open window of opportunity trials. J. Clin. Oncol. 30, 2573–2575 (2012).
  Article CAS PubMed Google Scholar
• Rustin, G., van der Burg, M., Griffin, C., Qian, W. & Swart, A. M. Early versus delayed treatment of relapsed ovarian cancer. Lancet 377, 380–381 (2011).
  Article PubMed Google Scholar
• Kotsopoulos, J. et al. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 137, 1136–1146 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Trabert, B. et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J. Natl. Cancer Inst. 106, djt431 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Baandrup, L., Kjaer, S. K., Olsen, J. H., Dehlendorff, C. & Friis, S. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann. Oncol. 4, 787–792 (2014).
  Google Scholar
• Kumar, S. et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 119, 555–562 (2013).
  Article CAS PubMed Google Scholar
• Lengyel, E. et al. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am. J. Obstet. Gynecol. 212, e1–479.e10 (2014).
  Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385, 1835–1842 (2015).
• Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 9, e1001200 (2012).
• Bristow, R. E. et al. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J. Natl Cancer Inst. 105, 823–832 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Norquist, B. M. et al. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol. Oncol. 128, 483–487 (2013).
  Article CAS PubMed Google Scholar
• Daniels, M. S. et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J. Clin. Oncol. 32, 1249–1255 (2014).
  Article PubMed PubMed Central Google Scholar
• Schrader, K. A. et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet. Gynecol. 120, 235–240 (2012).
  Article CAS PubMed Google Scholar
• Song, H. et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum. Mol. Genet. 23, 4703–4709 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014).
  Article CAS PubMed Google Scholar
• Manchanda, R. et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J. Natl Cancer Inst. 107, 380 (2015).
  PubMed Google Scholar
• Manchanda, R. et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J. Natl Cancer Inst. 107, 379 (2015).
  PubMed Google Scholar
• Meyer, L. A. et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet. Gynecol. 115, 945–952 (2010).
  Article PubMed PubMed Central Google Scholar
• Loveday, C. et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 44, 475–476 (2012).
  Article CAS PubMed Google Scholar
• Loveday, C. et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 43, 879–882 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Meindl, A. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 42, 410–414 (2010).
  Article CAS PubMed Google Scholar
• Rafnar, T. et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat. Genet. 43, 1104–1107 (2011).
  Article CAS PubMed Google Scholar
• Kuchenbaecker, K. B. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat. Genet. 47, 164–171 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Wenzel, L. et al. Biopsychological stress factors in BRCA mutation carriers. Psychosomatics 53, 582–590 (2012).
  Article PubMed PubMed Central Google Scholar
• Bell, K. Biomarkers, the molecular gaze and the transformation of cancer survivorship. Biosocieties 8, 124–143 (2013).
  Article PubMed PubMed Central Google Scholar
• Kwon, J. S. et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet. Gynecol. 121, 14–24 (2013).
  Article PubMed Google Scholar
• McAlpine, J. N. et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am. J. Obstet. Gynecol. 210, 471e1-11 (2014).
  Article Google Scholar
• Pearce, C. L. et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol. Biomarkers Prev. 24, 671–676 (2015).
  Article PubMed PubMed Central Google Scholar
• Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305, 2295–2303 (2011).
  Article CAS PubMed Google Scholar
• Menon, U. et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening. J. Clin. Oncol. 33, 2062–2071 (2015).
  Article PubMed PubMed Central Google Scholar
• Horowitz, N. S. et al. Does aggressive surgery improve outcomes? interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J. Clin. Oncol. 33, 937–943 (2015).
  Article PubMed PubMed Central Google Scholar
• Menon, U., Griffin, M. & Gentry-Maharaj, A. Ovarian cancer screening—current status, future directions. Gynecol. Oncol. 132, 490–495 (2014).
  Article PubMed PubMed Central Google Scholar
• Drescher, C. W. et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J. Clin. Oncol. 31, 387–392 (2013).
  Article PubMed Google Scholar
• Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl Med. 4, 136ra68 (2012).
  Article CAS PubMed Google Scholar
• Kinde, I. et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci. Transl Med. 5, 167ra4 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• McAlpine, J. N. et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol. Oncol. 120, 385–392 (2011).
  Article CAS PubMed Google Scholar
• Lutz, A. M. et al. Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin. Cancer Res. 20, 1313–1322 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Bristow, R. E., Montz, F. J., Lagasse, L. D., Leuchter, R. S. & Karlan, B. Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72, 278–287 (1999).
  Article CAS PubMed Google Scholar
• du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115, 1234–1244 (2009).
  Article CAS PubMed Google Scholar
• Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).
  Article CAS PubMed Google Scholar
• Naik, R., Edmondson, R. J., Galaal, K., Hatem, M. H. & Godfrey, K. A. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115, 1713–1714 (2008).
  CAS PubMed Google Scholar
• Enshaei, A., Robson, C. N. & Edmondson, R. J. Artificial intelligence systems as prognostic and predictive tools in ovarian cancer. Ann. Surg. Oncol. 22, 3970–3975 (2015).
  Article CAS PubMed Google Scholar
• van Meurs, H. S. et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur. J. Cancer 49, 3191–3201 (2013).
  Article PubMed Google Scholar
• Riester, M. et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl Cancer Inst. 106, dju048 (2014).
  Article PubMed PubMed Central Google Scholar
• Nick, A. M., Coleman, R. L., Ramirez, P. T. & Sood, A. K. A framework for a personalized surgical approach to ovarian cancer. Nat. Rev. Clin. Oncol. 12, 239–245 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Harter, P. et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int. J. Gynecol. Cancer 21, 289–295 (2011).
  Article PubMed Google Scholar
• Harter, P. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13, 1702–1710 (2006).
  Article PubMed Google Scholar
• Fotopoulou, C. et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann. Surg. Oncol. 20, 1348–1354 (2013).
  Article PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Mittag, J., Winterhager, E., Bauer, K. & Grummer, R. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 148, 719–725 (2007).
  Article CAS PubMed Google Scholar
• Tacha, D., Zhou, D. & Cheng, L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl. Immunohistochem Mol. Morphol. 19, 293–299 (2011).
  Article CAS PubMed Google Scholar
• Laury, A. R. et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am. J. Surg. Pathol. 34, 627–635 (2010).
  PubMed Google Scholar
• Whiteaker, J. R. et al. CPTAC Assay Portal: a repository of targeted proteomic assays. Nat. Methods 11, 703–704 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Aspuria, P. J. et al. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer Metab. 2, 21 (2014).
  Article PubMed PubMed Central Google Scholar
• Karst, A. M. et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol. Oncol. 123, 5–12 (2011).
  Article CAS PubMed PubMed Central Google Scholar